The stem cell market has been growing at a fast pace for the past few years and despite recession, the US continued to Read more…
Some shares of stem-cell companies regained lost ground by Friday, 2/25/11, after being pushed up and down during the week. Read more…
Few shares of stem-cell companies regained ground on Friday, 2/18/11, after being pushed up and down earlier in the week. Read more…
A new analyst review of Cytori Therapeutics. (NASDAQ:CYTX) entitled, “Targeting Ischemic Diseases by Improving Blood Flow.” Read more…
CUR updated the progress of its ongoing Phase I human clinical trial to treat ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig’s disease) at Emory University in Atlanta, Georgia. Read more…
Scimitar Equity, LLC has issued a review of Aastrom Biosciences, Inc. (NASDAQ:ASTM) entitled, “Three (3) Late Stage Trials Focus the Future Stock Appreciation”. Scimitar Equity maintains a BUY ranking. This review is available at website: ASTM Q3/10 Review Read more…
Three (3) human embryonic stem cell lines once eligible (5/4/10) for federal funding are “on hold” until further notice because they were derived from embryos that were too early. “These lines were derived from early embryos — those consisting of 6, 8, or 16 cells and thus formally did not fit the official definition of ES cells by the NIH,” Read more…
NIH Researchers have discovered bone-generating stem cells in the spine, at the end of the shins and in cartilage-rich areas of other bones. They also identified factors that control the growth of these stem cells, according to a report published (4/26/10) in the Proceedings of the National Academy of Sciences. The potential for this market is HUGE and will continue to grow as the population ages and minimally invasive surgeries and shorter hospital stays become a new standard. Read more…
Programs to create a new center for the study of stem cells and to increase capacity to deal with global health issues were among 7 scientific initiatives announced 2/25/10 by NIH Director Francis S. Collins, MD, PhD. The 7 research programs are supported through the NIH Common Fund, which encourages collaborative research programs across the NIH institutes and centers (IC) to accomplish work that no single IC could do alone. Read more…
Osiris Therapeutics is a stem cell therapeutic company focused on developing products in the inflammatory, orthopedic and cardiovascular areas. OSIR’s Q4/09 results reported achievement and data showing Prochymal achieved a 63% response rate when used as a rescue agent in children with end-stage GvHD with significant improvement in response rates over standard of care for both liver and gastrointestinal steroid-refractory GvHD – the two most deadly and difficult-to-treat forms of the disease. Graft-versus-host disease (GvHD) is a common complication of allogeneic bone marrow transplantation in which functional immune cells in the transplanted marrow recognize the recipient as “foreign” and mount an immunologic attack.
Founder and Director of Research, Henry McCusker enters his tenth (10) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.